| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/27/2000 | WO2000043397A1 Fused heterocyclic compounds and their use in the treatment of neurodegenerative diseases |
| 07/27/2000 | WO2000043395A1 Substituted porphyrins |
| 07/27/2000 | WO2000043394A1 Substituted nitrogen heterocyclic derivatives and pharmaceutical use thereof |
| 07/27/2000 | WO2000043393A1 Novel angiogenesis inhibitors |
| 07/27/2000 | WO2000043392A2 Use of imidazo[1,5-a]-pyrido[3,2-e]-pyrazinones as medicaments |
| 07/27/2000 | WO2000043391A1 Substituted 1-(pieridin-4-yl)-3-(aryl) isothioureas their preparation and therapeutic application |
| 07/27/2000 | WO2000043390A1 Antifungal azole derivatives having a fluorinated vinyl group and process for preparing same |
| 07/27/2000 | WO2000043387A1 New benzimidazole compounds for use as active therapeutic substances, process for the preparation of these compoudns and pharmaceutical compositions comprising them |
| 07/27/2000 | WO2000043384A1 Aromatic heterocyclic compounds as antiinflammatory agents |
| 07/27/2000 | WO2000043383A1 Piperidinylquinolines as protein tyrosine kinase inhibitors |
| 07/27/2000 | WO2000043382A1 Piperidine, tetrahydropyridine and piperazine derivatives, their preparation and use |
| 07/27/2000 | WO2000043378A1 New morpholinobenzamide salts |
| 07/27/2000 | WO2000043373A2 Kinase inhibitors |
| 07/27/2000 | WO2000043372A1 Acyl derivatives which treat vla-4 related disorders |
| 07/27/2000 | WO2000043371A2 Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 07/27/2000 | WO2000043370A1 Telmisartan polymorphs, methods for producing same and their use in the preparation of a medicament |
| 07/27/2000 | WO2000043369A1 Compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 07/27/2000 | WO2000043362A1 Phenylsulphonyl derivatives as 5-ht receptor ligands |
| 07/27/2000 | WO2000043354A2 Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 07/27/2000 | WO2000043353A1 Method for reducing 3-dimethylamino-2-phenylpropion-acid ethyl ester-content in solutions of 2-dimethylamino-1-phenyl-3-cyclohexene-1-carboxylic acid ethyl ester |
| 07/27/2000 | WO2000043350A1 Crystal polymorphism of aminoethylphenoxyacetic acid derivative |
| 07/27/2000 | WO2000043058A1 Method of enhancing needleless transdermal powdered drug delivery |
| 07/27/2000 | WO2000043042A1 Parenteral metolazone formulations |
| 07/27/2000 | WO2000043039A1 Vaccine-mediated treatment of neurological disorders |
| 07/27/2000 | WO2000043038A1 Methods and devices for delivery of agents to breast milk ducts |
| 07/27/2000 | WO2000043032A2 Baff, inhibitors thereof and their use in the modulation of b-cell response |
| 07/27/2000 | WO2000043018A1 Medicinal compositions |
| 07/27/2000 | WO2000043017A1 Composition of anti-hiv drugs and anti-cortisol compounds and method for decreasing the side effects of anti-hiv drugs in a human |
| 07/27/2000 | WO2000043015A1 Eye drops |
| 07/27/2000 | WO2000043014A2 Beta-d-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine for use in the treatment of hiv infections |
| 07/27/2000 | WO2000043013A1 Pharmaceutical compositions for alleviating discomfort |
| 07/27/2000 | WO2000043012A1 Controlling heart rate or blood pressure in patients co-medicated with phosphodiesterase inhibitors for treatment of impotence |
| 07/27/2000 | WO2000043011A1 Substituted 1-(piperidin-4-yl)-3-(aryl)-isothioureas, their preparation and therapeutic use |
| 07/27/2000 | WO2000043010A1 Acyl derivatives of 4-demethylpenclomedine, use thereof and preparation thereof |
| 07/27/2000 | WO2000043009A1 Pyridine compounds, use and preparation thereof |
| 07/27/2000 | WO2000043008A1 Anti-androgens and methods for treating disease |
| 07/27/2000 | WO2000043007A1 Troglitazone-containing medicinal compositions for inhibiting apoptosis |
| 07/27/2000 | WO2000043006A1 Inhibitor for nerve cell death due to glutamic acid cytotoxicity |
| 07/27/2000 | WO2000043003A1 The therapeutic use of r-warfarin as anticoagulant |
| 07/27/2000 | WO2000043002A1 Method to aid smoking cessation |
| 07/27/2000 | WO2000043001A1 Anti-inflammatory agents |
| 07/27/2000 | WO2000042999A1 Phenylpropionic acids and ester compounds and methods for inducing beta-blockade |
| 07/27/2000 | WO2000042998A1 Multiparticulate bisoprolol formulation |
| 07/27/2000 | WO2000042997A1 Medicinal compositions retarded in the discoloration of phenolic hydroxyl compounds |
| 07/27/2000 | WO2000042996A2 Use of anticonvulsant derivatives for treating cluster headaches |
| 07/27/2000 | WO2000042995A2 Use of anticonvulsant derivatives for treating transformed migraine |
| 07/27/2000 | WO2000042994A2 Inhibition of bacterial dissemination |
| 07/27/2000 | WO2000042993A2 Nonaqueous solutions and suspensions of macromolecules for pulmonary delivery |
| 07/27/2000 | WO2000042992A2 Compositions and methods for mucosal delivery |
| 07/27/2000 | WO2000042990A1 Liposome formulations |
| 07/27/2000 | WO2000042989A2 Novel hydrogel isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules |
| 07/27/2000 | WO2000042987A2 Targeted vesicular constructs for cytoprotection and treatment of h. pylori infections |
| 07/27/2000 | WO2000042982A1 Methods and kits for removing, treating, or preventing lice with driable pediculostatic agents |
| 07/27/2000 | WO2000042955A1 Drug dosage unit for buccal administration of steroidal active agents |
| 07/27/2000 | WO2000042942A2 Buccal drug delivery system for use in male contraception |
| 07/27/2000 | WO2000042868A1 Infant formula |
| 07/27/2000 | WO2000042864A2 Methods for reducing mortality rates in poultry |
| 07/27/2000 | WO2000042861A1 Chewing gum with dental health benefits employing calcium lactate |
| 07/27/2000 | WO2000042854A1 Multi-purpose acid compositions |
| 07/27/2000 | WO2000042852A1 Compounds and methods |
| 07/27/2000 | WO2000042849A1 COMPLEX OF RAS-FARNESYLTRANSFERASE INHIBITOR AND SULFOBUTYLETHER-7-β-CYCLODEXTRIN OR 2-HYDROXYPROPYL-β-CYCLODEXTRIN AND METHOD |
| 07/27/2000 | WO2000042848A1 Medicinal composition and its process of preparation |
| 07/27/2000 | WO2000042842A1 Organoprotective solutions |
| 07/27/2000 | WO2000042841A1 Methods for identifying, treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer |
| 07/27/2000 | WO2000042832A2 New compounds for the treatment of cancer |
| 07/27/2000 | WO2000028980A3 Combination of duloxetine with non-steroidal antiinflammatory drug for treating pain |
| 07/27/2000 | WO2000027832A3 Thiazole derivatives as ppar gamma ligands |
| 07/27/2000 | WO2000025723A3 Methods and compositions for the prevention of tolerance to medications |
| 07/27/2000 | WO2000023618B1 Polymorphism in a tgf-beta gene correlated to osteoporosis |
| 07/27/2000 | WO2000023588A3 G-protein coupled receptors |
| 07/27/2000 | WO2000023433A8 Substituted benzopyran analogs for the treatment of inflammation |
| 07/27/2000 | WO2000023096A3 Combination therapy with vip antagonist |
| 07/27/2000 | WO2000023086A3 Buffered compositions for dialysis |
| 07/27/2000 | WO2000023068A3 Fumaric acid microtablets |
| 07/27/2000 | WO2000023062A3 Irrigation solution and method for inhibition of pain and inflammation |
| 07/27/2000 | WO2000023057A3 Atypical antiphsychotic in combination with acetylcholinesterase inhibitor for improving cognition |
| 07/27/2000 | WO2000021550A3 Methods and compositions for treating neurodegenerative diseases |
| 07/27/2000 | WO2000021507A3 Pharmaceutically active composition |
| 07/27/2000 | WO2000021492A3 Cream cleanser with high levels of emollients and glycerin |
| 07/27/2000 | WO2000019997A8 Controlled release dosage from comprising oxybutynin |
| 07/27/2000 | WO2000018767A3 2-piperazino alkylamino benzoazole derivatives: dopamine receptor subtype specific ligands |
| 07/27/2000 | WO2000018358A3 Method of treating hair loss using ketoamides |
| 07/27/2000 | WO2000018232A8 Method of treatment of cardiovascular injuries |
| 07/27/2000 | WO2000013662A8 Medicated chewing gum delivery system for nicotine |
| 07/27/2000 | WO2000009111A9 Inhibitors of amyloid formation |
| 07/27/2000 | WO2000008202A9 3-methylidenyl-2-indolinone modulators of protein kinase |
| 07/27/2000 | WO2000004157A3 Cloning and characterisation of novel mammalian peptidases |
| 07/27/2000 | WO1999066944A9 Methods for identifying novel multimeric agents that modulate receptors |
| 07/27/2000 | WO1999064033A9 Phosphodiesterase-v modulator drugs and their uses |
| 07/27/2000 | WO1999063994A9 MULTIBINDING INHIBITORS OF HMG-CoA REDUCTASE |
| 07/27/2000 | WO1999062881A8 Aza-heterocyclic compounds used to treat neurological disorders and hair loss |
| 07/27/2000 | WO1999060987A8 Control of pain with endogenous cannabinoids |
| 07/27/2000 | WO1999055322A9 Use of nmda antagonists and/or sodium channel antagonists for the treatment of inflammatory disorders |
| 07/27/2000 | DE19926890C1 Use of highly fluorinated oligomeric alkanes in ophthalmology, especially as vitreous humor substitutes, retinal tamponade materials, liquid implants, tear fluid substitutes and drug carriers |
| 07/27/2000 | DE19902773A1 Anticholestatische Wirksamkeit von Luteolin Anticholestatic effectiveness of luteolin |
| 07/27/2000 | DE19902590A1 Removal of ethyl 3-dimethylamino-2-phenylpropionate from ethyl 2-dimethylamino-1-phenyl-3-cyclohexene-1-carboxylate solution comprises treatment with carboxylic acid |
| 07/27/2000 | DE10003356A1 Novel ribozymes targeted against the catalytic subunit of the human telomerase enzyme reverse transcriptase are useful for treating tumors |
| 07/27/2000 | CA2627837A1 Pharmaceutical compositions for alleviating discomfort |
| 07/27/2000 | CA2366844A1 Methods and kits for removing, treating, or preventing lice with driable pediculostatic agents |
| 07/27/2000 | CA2361272A1 33 human secreted proteins |